Back to search
FDAFDA · Food and drugs·Recall number D-0129-2019

Metoprolol Succinate Extended Release Tablets, USP 50 mg, 100-count bottle, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, NDC 62037-831-01

Published October 31, 2018 · Recall initiated: October 19, 2018

Summary

FDA records drug Class II recall D-0129-2019, published October 31, 2018 and initiated October 19, 2018. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 53,451 bottles; Lot: Lot # 1220211M, Exp 02/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications: Out-of-Specification dissolution test result obtained during routine stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
U.S.A. Nationwide including Puerto Rico.
Lot
Lot # 1220211M, Exp 02/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metoprolol Succinate Extended Release Tablets, USP 50 mg, 100-count bottle, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, NDC 62037-831-01 recalled?

Yes. FDA published recall D-0129-2019 on October 31, 2018. Reported hazard: Failed dissolution specifications: Out-of-Specification dissolution test result obtained during routine stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter